Glucose metabolism in patients with essential hypertension

被引:113
作者
García-Puig, J
Ruilope, LM
Luque, M
Fernández, J
Ortega, R
Dal-Ré, R
机构
[1] Hosp Univ La Paz, Gen Hosp, Med Interna Serv, Div Internal Med, Madrid 28046, Spain
[2] Hosp Univ 12 Octubre, Hypertens Unit, Madrid, Spain
[3] Hosp Clin Univ, Hypertens Unit, Madrid, Spain
[4] GlaxoSmithKline, Dept Med, Madrid, Spain
关键词
insulin resistance; hypertension; type; 2; diabetes; impaired fasting glucose; impaired glucose tolerance; left ventricular hypertrophy;
D O I
10.1016/j.amjmed.2005.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension. Methods: In this cross-sectional study, 420 consecutively referred essential hypertensive patients were studied at 16 hypertension clinics in university and community hospitals of Spain. Fasting and 2-hour plasma glucose and insulin levels were determined in nondiabetic patients. Results: An abnormal glucose metabolism was diagnosed in 68.5% (95% confidence interval [CI], 63.7%-72.9%) of the patients. Isolated insulin resistance, defined by a homeostasis model assessment-estimated insulin resistance (HOMA-IR) equal to or above 3.8, was shown in 9.3% (95% CI, 6.7%-12.5%); impaired fasting glucose in 11.2% (95% CI, 8.6%-14.7%); impaired glucose tolerance in 22.5% ( 95% CI, 18.5%-26.9%); silent undiagnosed type 2 diabetes in 11.5% (95% CI, 8.6%-14.5%); and known diabetes mellitus in 13.9% (95% CI, 10.4%-17.2%) of the patients. According to the European Group for the Study of Insulin Resistance and the Adult Treatment Program III criteria, the metabolic syndrome was diagnosed in 41.5% (95% CI, 35.9%-47.3%) and 47.9% (95% CI, 43.1%-52.8%) of the patients, respectively. The prevalence of left ventricular hypertrophy (defined by a left ventricular mass index [LVMI] >125 g/m(2)) was 44.2%. The relation between HOMA-IR and LVMI was statistically nonsignificant, and the LVMI values in the HOMA-IR quartiles were similar. Only 27 patients (6.4%) showed good control of cardiovascular risk factors. In most patients (273, 65%; 95% CI, 60.3%-69.4%) 2 or more cardiovascular risk factors were identified as not being under control. Conclusions: Two thirds of the patients attending hypertension clinics with essential hypertension show an abnormal glucose metabolism. The metabolic syndrome can be identified in a substantial number of these patients, and 2 or more cardiovascular risk factors are not controlled in the majority of patients. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:318 / 326
页数:9
相关论文
共 55 条
  • [1] Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population
    Ascaso, JF
    Romero, P
    Real, JT
    Priego, A
    Valdecabres, C
    Carmena, R
    [J]. MEDICINA CLINICA, 2001, 117 (14): : 530 - 533
  • [2] Balkau B, 2002, DIABETES METAB, V28, P364
  • [3] Screening for type 2 diabetes mellitus in adults: Recommendations and rationale
    Berg, AO
    Allan, JD
    Frame, P
    Homer, CJ
    Johnson, MS
    Klein, JD
    Lieu, TA
    Orleans, CT
    Peipert, JF
    Pender, NJ
    Sin, AL
    Teutsch, SM
    Westhoff, C
    Woolf, SH
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) : 212 - 214
  • [4] Borch-Johnsen K, 1999, LANCET, V354, P617
  • [5] Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study
    Castell, C
    Tresserras, R
    Serra, J
    Goday, A
    Lloveras, G
    Salleras, L
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 1999, 43 (01) : 33 - 40
  • [6] Chalmers J, 1999, J HYPERTENS, V17, P151
  • [7] Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. LANCET, 2002, 359 (9323) : 2072 - 2077
  • [8] Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial
    Chiasson, JL
    Josse, RG
    Gomis, R
    Hanefeld, M
    Karasik, A
    Laakso, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04): : 486 - 494
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study
    de Simone, G
    Palmieri, V
    Bella, JN
    Celentano, A
    Hong, YL
    Oberman, A
    Kitzman, DW
    Hopkins, PN
    Arnett, DK
    Devereux, RB
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (02) : 323 - 331